WHO issues new and updated recommendations on treatment of mental, neurological and substance use conditions
The World Health Organization (WHO) has today published the third edition of the Mental Health Gap Action Programme (mhGAP) guideline which includes important new, and updated, recommendations for the treatment and care of mental, neurological and substance use (MNS) disorders. MNS disorders are major contributors to morbidity and premature mortality in all regions of the world. Yet it is estimated that over 75% of people with MNS disorders are unable to access the treatment or care they need.
Other Articles in this Edition
People taking ADHD medications should closely monitor their heart health, study suggests
Psychiatric Comorbidity Increases Risk for Schizophrenia With ADHD
New study sheds light on ADHD’s impact on motivation and the efficacy of amphetamine-based meds
Microdosing psychedelics shows promise for improving mindfulness in adults with ADHD
Texas AG sues Pfizer over quality-control lapses in kids’ ADHD drug
US Limit on a Key ADHD Drug Is Worsening Shortages, Group Says
Diagnosed With ADHD — What Should I Do Now?
What it’s like to be diagnosed with ADHD as an adult in China